Can Growth Factors Cure Parkinson's Disease?

Trends Pharmacol Sci. 2020 Dec;41(12):909-922. doi: 10.1016/j.tips.2020.09.010. Epub 2020 Oct 22.

Abstract

Growth factors (GFs) hold considerable promise for disease modification in neurodegenerative disorders because they can protect and restore degenerating neurons and also enhance their functional activity. However, extensive efforts applied to utilize their therapeutic potential in humans have achieved limited success so far. Multiple clinical trials with GFs were performed in Parkinson's disease (PD) patients, in whom diagnostic symptoms of the disease are caused by advanced degeneration of nigrostriatal dopamine neurons (DNs), but the results of these trials are controversial. This review discusses recent developments in the field of therapeutic use of GFs, problems and obstacles related to this use, suggests the ways to overcome these issues, and alternative approaches that can be used to utilize the potential ofGFsin PD management.

Keywords: Parkinson’s disease; dopamine neurons; glial cell line-derived neurotrophic factor family ligands; neurotrophic factors; neurturin, cerebral dopamine neurotrophic factor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Dopaminergic Neurons
  • Humans
  • Intercellular Signaling Peptides and Proteins* / therapeutic use
  • Neurodegenerative Diseases*
  • Parkinson Disease* / drug therapy

Substances

  • Intercellular Signaling Peptides and Proteins